SCHEMBL7047384

SCHEMBL7047384

COc1cncc(CC2CCC3CCN2C3)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 11/20 0.39
CHRNA4 P43681 11/20 0.39
CHRNA7 P36544 2/20 0.39
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
CHRNB4 P30926 6/20 0.37
CHRNA3 P32297 6/20 0.37
DAPK3 O43293 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKCG P05129 1/20 0.36
PIM1 P11309 1/20 0.36
RPS6KB1 P23443 1/20 0.36
AKT1 P31749 1/20 0.36
LIMK1 P53667 1/20 0.36
CDK5 Q00535 1/20 0.36
PRKCD Q05655 1/20 0.36
PAK1 Q13153 1/20 0.36
STK3 Q13188 1/20 0.36
ROCK1 Q13464 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7040540 0.91 CHRNB2 (0.46) CHRNB2CHRNA4CHRNA7KDM1AMAOA
SCHEMBL7042416 0.88 CHRNB2 (0.44) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL7045960 0.86 CHRNB2 (0.39) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL7046934 0.86 CHRNB2 (0.37) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL7045702 0.85 CHRNB2 (0.55) CHRNB2CHRNA4CHRNA7KDM1AMAOA
SCHEMBL7045508 0.81 CHRNB2 (0.45) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL7042417 0.79 CHRNB2 (0.44) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL7046955 0.78 CHRNB2 (0.43) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL7042402 0.78 CHRNB2 (0.43) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL701068 0.73 CHRNA7 (0.72) CHRNB2CHRNA4CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030045523-A1 Nicotinic cholinergic receptor antagonists SCHMITT JEFFREY DANIEL (US) 2003-03-06 US disclosed
US-6432975-B1 AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT TARGACEPT, INC. 2002-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045523-A1 Nicotinic cholinergic receptor antagonists CHRNG, CHRNB1, CHRNA1 CHRNB2 9/4885CHRNA4 13/4885CHRNA7 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.